The Economist - Phase 3 of the Health Inclusivity Index

Zurich, Switzerland | 22 May, 2025 | BY: The Economist

We are pleased to share that phase 3 of the Health Inclusivity Index has been launched, and can be accessed at Index website, along with the findings from phases 1 and 2.

The third research phase examines the health and economic impacts of removing barriers that prevent good health for underserved population segments. It focuses on seven health topics (health literacy, air pollution, tooth decay, gum disease and type 2 diabetes, micronutrient deficiency, musculoskeletal conditions and osteoporosis) across four groups who often face significant barriers to healthcare access or experience a higher burden of certain conditions: people with low health literacy, those with low incomes, women, and individuals aged 50 and above. The results of these analyses are described in a report, an interactive data story, and snapshots for each of the 40 countries in the Index.

Phase 3 also includes forcefield analysis and stakeholder mapping to create health inclusivity roadmaps for five countries (Brazil, Germany, India, Indonesia, and South Africa). These outline the steps that countries can take, and which stakeholders would be best placed to implement them. 

We are here to transform medicine and healthcare towards precision medicine. Right now, there is a critical need for your support. Donate today and help us continue to study Sex and Gender differences impacting brain and mental diseases.

Health begins with human beings, individuals – men and women are different when it comes to brain and mental disease frequency, severity, symptomatology, risk factors and even response to treatments. Thanks to the gifts from supporters like you the scientific community is starting to take note. We have shown the world that in diseases like Alzheimer’s for instance, disease progression is faster in women than men and women show different levels of biomarkers.

Our goal is to clearly identify such differences in diseases, diagnostic, and treatments, as well as novel technologies, and leverage them for better solutions. We ask for better clinical outcomes, better care, and innovative artificial intelligence (AI)-based solutions. Sex and gender differences are the first steps towards precision medicine, which acknowledges the specific needs of each patient. Our ultimate ambition is the realisation of the Research Institute for Sex and Gender Precision Medicine.